STX — Shield Therapeutics Balance Sheet
0.000.00%
- £26.82m
- £41.50m
- $32.18m
- 25
- 24
- 43
- 17
Annual balance sheet for Shield Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | fx Final | Final | Final | Final | Final |
Cash | |||||
Cash and Short Term Investments | 4.02 | 16.3 | 3.4 | 13.9 | 6.52 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.897 | 4.73 | 4.51 | 11.2 | 22.8 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 7.15 | 23.3 | 12.2 | 31.3 | 37.9 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.044 | 0.41 | 0.238 | 0.673 | 0.373 |
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 44.5 | 59.9 | 26.6 | 48.8 | 57.5 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 3.08 | 4.56 | 12.8 | 13.7 | 32.6 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Liabilities | 3.08 | 4.56 | 20.1 | 33.8 | 58.8 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 41.4 | 55.4 | 6.54 | 15 | -1.32 |
Total Liabilities & Shareholders' Equity | 44.5 | 59.9 | 26.6 | 48.8 | 57.5 |
Total Common Shares Outstanding |